Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to- Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
NCT07296315 is registered in ClinicalTrials.gov with MRM Health NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to- Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
- Lead sponsor
- MRM Health NV
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 3, 2026
- Completion date
- May 31, 2028
- Enrollment
- 204 (estimated)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.